| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Warfarin | 21 | 2026 | 67 | 7.130 |
Why?
|
| Anticoagulants | 19 | 2026 | 122 | 4.920 |
Why?
|
| Pharmacogenetics | 21 | 2026 | 67 | 4.490 |
Why?
|
| Platelet Aggregation Inhibitors | 10 | 2024 | 77 | 4.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 10 | 2023 | 51 | 2.770 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2024 | 863 | 1.930 |
Why?
|
| Genotype | 19 | 2024 | 800 | 1.770 |
Why?
|
| Ticlopidine | 4 | 2018 | 17 | 1.620 |
Why?
|
| Aryldialkylphosphatase | 4 | 2024 | 14 | 1.620 |
Why?
|
| Algorithms | 7 | 2024 | 509 | 1.480 |
Why?
|
| Mixed Function Oxygenases | 6 | 2012 | 31 | 1.210 |
Why?
|
| Cardiovascular Diseases | 4 | 2024 | 749 | 1.180 |
Why?
|
| Thrombosis | 3 | 2018 | 81 | 1.070 |
Why?
|
| Humans | 75 | 2026 | 43102 | 1.060 |
Why?
|
| Blood Platelets | 2 | 2018 | 81 | 1.040 |
Why?
|
| Acute Coronary Syndrome | 3 | 2024 | 42 | 0.990 |
Why?
|
| Puerto Rico | 13 | 2026 | 1413 | 0.960 |
Why?
|
| Polymorphism, Genetic | 5 | 2021 | 201 | 0.960 |
Why?
|
| Antibodies, Monoclonal | 9 | 2008 | 306 | 0.920 |
Why?
|
| Ascorbic Acid | 4 | 2012 | 74 | 0.880 |
Why?
|
| Diabetic Neuropathies | 2 | 2017 | 12 | 0.870 |
Why?
|
| Aged | 16 | 2026 | 8214 | 0.810 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2019 | 13 | 0.790 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 34 | 0.700 |
Why?
|
| Male | 29 | 2026 | 23409 | 0.690 |
Why?
|
| Mutation, Missense | 2 | 2018 | 91 | 0.680 |
Why?
|
| Hemorrhage | 2 | 2024 | 55 | 0.640 |
Why?
|
| Pharmaceutical Preparations | 4 | 2024 | 94 | 0.610 |
Why?
|
| Female | 27 | 2026 | 24698 | 0.600 |
Why?
|
| Middle Aged | 15 | 2026 | 12222 | 0.580 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2026 | 1124 | 0.580 |
Why?
|
| Metformin | 2 | 2017 | 75 | 0.560 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2017 | 760 | 0.550 |
Why?
|
| Tetrazoles | 1 | 2018 | 46 | 0.540 |
Why?
|
| Stents | 2 | 2018 | 67 | 0.530 |
Why?
|
| Caribbean Region | 4 | 2024 | 79 | 0.530 |
Why?
|
| Drug Resistance | 1 | 2017 | 96 | 0.510 |
Why?
|
| Carotid Artery Diseases | 1 | 2017 | 26 | 0.500 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 43 | 0.500 |
Why?
|
| Gene Frequency | 6 | 2020 | 206 | 0.490 |
Why?
|
| Drug Combinations | 1 | 2015 | 104 | 0.460 |
Why?
|
| Drug Interactions | 1 | 2015 | 150 | 0.450 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2016 | 20 | 0.440 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 122 | 0.430 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 307 | 0.420 |
Why?
|
| Neoplasms | 4 | 2022 | 1377 | 0.410 |
Why?
|
| Vitamins | 3 | 2015 | 81 | 0.380 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 259 | 0.370 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 2853 | 0.360 |
Why?
|
| Metabolic Clearance Rate | 2 | 2008 | 30 | 0.350 |
Why?
|
| Psychotic Disorders | 1 | 2012 | 71 | 0.340 |
Why?
|
| Chemistry, Pharmaceutical | 4 | 2025 | 97 | 0.340 |
Why?
|
| Haplotypes | 4 | 2024 | 197 | 0.340 |
Why?
|
| Dietary Supplements | 2 | 2015 | 213 | 0.340 |
Why?
|
| Treatment Outcome | 4 | 2020 | 1604 | 0.330 |
Why?
|
| Metagenomics | 1 | 2009 | 46 | 0.290 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2005 | 18 | 0.290 |
Why?
|
| Polyethylene Glycols | 2 | 2026 | 108 | 0.280 |
Why?
|
| Problem-Based Learning | 1 | 2008 | 42 | 0.280 |
Why?
|
| Technology, Pharmaceutical | 2 | 2025 | 35 | 0.280 |
Why?
|
| Risk Assessment | 2 | 2024 | 863 | 0.280 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 7 | 0.280 |
Why?
|
| Education, Pharmacy | 1 | 2008 | 57 | 0.270 |
Why?
|
| Drug Compounding | 2 | 2025 | 93 | 0.270 |
Why?
|
| Clinical Competence | 1 | 2008 | 156 | 0.270 |
Why?
|
| Epidermal Growth Factor | 2 | 2004 | 70 | 0.260 |
Why?
|
| Heart Failure | 1 | 2010 | 302 | 0.260 |
Why?
|
| Enzymes | 3 | 2015 | 35 | 0.250 |
Why?
|
| Half-Life | 4 | 2016 | 63 | 0.250 |
Why?
|
| Micronutrients | 3 | 2015 | 45 | 0.250 |
Why?
|
| Risk Factors | 5 | 2017 | 3994 | 0.250 |
Why?
|
| Retrospective Studies | 4 | 2019 | 2544 | 0.240 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2015 | 98 | 0.240 |
Why?
|
| Hematinics | 1 | 2026 | 9 | 0.240 |
Why?
|
| Erythropoietin | 1 | 2026 | 38 | 0.240 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 3156 | 0.240 |
Why?
|
| Anemia | 1 | 2026 | 55 | 0.230 |
Why?
|
| Alleles | 4 | 2024 | 352 | 0.230 |
Why?
|
| Biological Products | 1 | 2006 | 91 | 0.220 |
Why?
|
| Area Under Curve | 6 | 2007 | 95 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2004 | 347 | 0.210 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 54 | 0.210 |
Why?
|
| Methadone | 1 | 2024 | 24 | 0.210 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2024 | 14 | 0.210 |
Why?
|
| Mice, Nude | 7 | 2015 | 408 | 0.200 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 29 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2020 | 1759 | 0.190 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2026 | 193 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2020 | 1600 | 0.190 |
Why?
|
| West Indies | 1 | 2021 | 13 | 0.180 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2021 | 25 | 0.180 |
Why?
|
| Injections, Intravenous | 3 | 2008 | 67 | 0.180 |
Why?
|
| Endocytosis | 1 | 2002 | 118 | 0.170 |
Why?
|
| Buprenorphine | 1 | 2021 | 51 | 0.170 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 423 | 0.170 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2021 | 50 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 638 | 0.170 |
Why?
|
| Platelet Aggregation | 2 | 2018 | 21 | 0.170 |
Why?
|
| Rabbits | 3 | 2026 | 278 | 0.170 |
Why?
|
| Dinucleoside Phosphates | 1 | 2020 | 11 | 0.170 |
Why?
|
| Thromboembolism | 1 | 2020 | 20 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 61 | 0.160 |
Why?
|
| Apoptosis | 1 | 2008 | 1568 | 0.160 |
Why?
|
| Adult | 8 | 2019 | 13872 | 0.160 |
Why?
|
| United States | 6 | 2020 | 5205 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2024 | 972 | 0.150 |
Why?
|
| Mice | 10 | 2021 | 6644 | 0.150 |
Why?
|
| Animals | 16 | 2026 | 16992 | 0.150 |
Why?
|
| Linear Models | 2 | 2017 | 317 | 0.150 |
Why?
|
| Geography | 1 | 2019 | 110 | 0.150 |
Why?
|
| Coenzymes | 2 | 2015 | 13 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 195 | 0.140 |
Why?
|
| Models, Biological | 3 | 2026 | 712 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2018 | 25 | 0.140 |
Why?
|
| Recombinant Proteins | 5 | 2026 | 518 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2018 | 760 | 0.140 |
Why?
|
| Malnutrition | 2 | 2015 | 44 | 0.140 |
Why?
|
| Genetic Markers | 1 | 2018 | 150 | 0.140 |
Why?
|
| Heterozygote | 2 | 2015 | 110 | 0.140 |
Why?
|
| Budesonide | 1 | 2017 | 5 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 1092 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 234 | 0.130 |
Why?
|
| Drug Synergism | 1 | 2018 | 195 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 1019 | 0.130 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 236 | 0.130 |
Why?
|
| Particulate Matter | 1 | 2017 | 83 | 0.130 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 4 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 440 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 247 | 0.120 |
Why?
|
| Legislation, Drug | 1 | 2015 | 5 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 19 | 0.120 |
Why?
|
| Homozygote | 1 | 2015 | 77 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2017 | 587 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2019 | 380 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 195 | 0.110 |
Why?
|
| Energy Metabolism | 2 | 2015 | 187 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2015 | 63 | 0.110 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2015 | 26 | 0.110 |
Why?
|
| Carbazoles | 1 | 2015 | 49 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 40 | 0.110 |
Why?
|
| Logistic Models | 1 | 2017 | 1009 | 0.110 |
Why?
|
| Phenotype | 1 | 2017 | 780 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2015 | 139 | 0.100 |
Why?
|
| Tissue Distribution | 6 | 2006 | 240 | 0.100 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 184 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2015 | 389 | 0.100 |
Why?
|
| Prevalence | 3 | 2019 | 1612 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 235 | 0.100 |
Why?
|
| Time Factors | 2 | 2010 | 1857 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 590 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 465 | 0.090 |
Why?
|
| Drugs, Generic | 1 | 2012 | 6 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 241 | 0.090 |
Why?
|
| Prescription Drugs | 1 | 2012 | 32 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2012 | 490 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2016 | 502 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2010 | 9 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 223 | 0.080 |
Why?
|
| Analgesics, Opioid | 2 | 2024 | 252 | 0.080 |
Why?
|
| Technetium | 2 | 1999 | 11 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2000 | 62 | 0.080 |
Why?
|
| Disease Progression | 1 | 2011 | 667 | 0.070 |
Why?
|
| Competency-Based Education | 1 | 2008 | 11 | 0.070 |
Why?
|
| Injections, Subcutaneous | 2 | 2005 | 36 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 1 | 2009 | 74 | 0.070 |
Why?
|
| Thrombophlebitis | 1 | 2008 | 2 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 53 | 0.070 |
Why?
|
| Immunoconjugates | 2 | 1999 | 8 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2009 | 91 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2008 | 141 | 0.070 |
Why?
|
| Patient-Centered Care | 1 | 2008 | 75 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2024 | 430 | 0.070 |
Why?
|
| Rats, Wistar | 3 | 2004 | 283 | 0.070 |
Why?
|
| Biological Availability | 1 | 2008 | 116 | 0.070 |
Why?
|
| Students, Pharmacy | 1 | 2008 | 58 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 2008 | 104 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2008 | 260 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 153 | 0.060 |
Why?
|
| gamma-Globulins | 1 | 2006 | 5 | 0.060 |
Why?
|
| Licensure | 1 | 2006 | 5 | 0.060 |
Why?
|
| Drug and Narcotic Control | 1 | 2006 | 12 | 0.060 |
Why?
|
| Drug Industry | 1 | 2006 | 18 | 0.060 |
Why?
|
| Genomics | 1 | 2008 | 293 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2004 | 495 | 0.060 |
Why?
|
| Tablets | 1 | 2025 | 14 | 0.060 |
Why?
|
| Capsules | 1 | 2025 | 28 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2026 | 113 | 0.060 |
Why?
|
| Crystallization | 1 | 2025 | 88 | 0.060 |
Why?
|
| Sulfhydryl Compounds | 2 | 2022 | 51 | 0.060 |
Why?
|
| Solvents | 1 | 2025 | 113 | 0.060 |
Why?
|
| Nutritional Requirements | 2 | 2015 | 33 | 0.060 |
Why?
|
| Minerals | 2 | 2015 | 53 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 506 | 0.050 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 41 | 0.050 |
Why?
|
| Food | 2 | 2015 | 103 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2004 | 43 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 508 | 0.050 |
Why?
|
| Dogs | 1 | 2004 | 204 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2026 | 408 | 0.050 |
Why?
|
| Species Specificity | 1 | 2004 | 286 | 0.050 |
Why?
|
| Bronchi | 2 | 2017 | 45 | 0.050 |
Why?
|
| Rats | 4 | 2004 | 3735 | 0.050 |
Why?
|
| Acetylcysteine | 1 | 2022 | 57 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 133 | 0.050 |
Why?
|
| Naloxone | 1 | 2021 | 56 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2004 | 195 | 0.040 |
Why?
|
| Glutathione | 1 | 2022 | 171 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2021 | 78 | 0.040 |
Why?
|
| Knowledge Bases | 1 | 2021 | 8 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 158 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 28 | 0.040 |
Why?
|
| Skin | 1 | 2002 | 187 | 0.040 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2020 | 18 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 84 | 0.040 |
Why?
|
| Universities | 1 | 2024 | 559 | 0.040 |
Why?
|
| Organotechnetium Compounds | 1 | 1999 | 9 | 0.040 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 6 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2019 | 104 | 0.040 |
Why?
|
| Antioxidants | 1 | 2022 | 443 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 355 | 0.040 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2018 | 58 | 0.040 |
Why?
|
| Technetium Compounds | 1 | 1998 | 3 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2017 | 74 | 0.030 |
Why?
|
| HLA-A Antigens | 1 | 2016 | 7 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2016 | 11 | 0.030 |
Why?
|
| Central America | 1 | 2016 | 13 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 165 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1999 | 291 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 455 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1596 | 0.030 |
Why?
|
| Avitaminosis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2015 | 17 | 0.030 |
Why?
|
| Drinking Behavior | 1 | 2015 | 18 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1455 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 29 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2015 | 90 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2015 | 39 | 0.030 |
Why?
|
| Therapeutic Equivalency | 2 | 2005 | 4 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 90 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 173 | 0.030 |
Why?
|
| Magnesium | 1 | 2015 | 94 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 2006 | 38 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2015 | 48 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2005 | 115 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 137 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2676 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2017 | 434 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 945 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2005 | 317 | 0.030 |
Why?
|
| Cell Line | 1 | 2017 | 1410 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 359 | 0.020 |
Why?
|
| Lipids | 1 | 2015 | 256 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 611 | 0.020 |
Why?
|
| DNA Damage | 1 | 2015 | 356 | 0.020 |
Why?
|
| Fermentation | 1 | 2012 | 39 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 737 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 5080 | 0.020 |
Why?
|
| Glycolysis | 1 | 2012 | 71 | 0.020 |
Why?
|
| Radioligand Assay | 2 | 2002 | 65 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 388 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2015 | 469 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1081 | 0.020 |
Why?
|
| Oxygen | 1 | 2012 | 218 | 0.020 |
Why?
|
| Child | 1 | 2019 | 3443 | 0.020 |
Why?
|
| Genetic Privacy | 1 | 2010 | 2 | 0.020 |
Why?
|
| Thiophenes | 1 | 2010 | 32 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2012 | 403 | 0.020 |
Why?
|
| Freeze Drying | 2 | 2000 | 29 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2000 | 98 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2000 | 129 | 0.020 |
Why?
|
| Piperazines | 1 | 2010 | 120 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 43 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 179 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 638 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 64 | 0.020 |
Why?
|
| Isotope Labeling | 2 | 1999 | 26 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 207 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 523 | 0.020 |
Why?
|
| Health Policy | 1 | 2010 | 184 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 6081 | 0.020 |
Why?
|
| Trachea | 1 | 2006 | 25 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 1151 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2006 | 89 | 0.020 |
Why?
|
| DNA | 1 | 2009 | 592 | 0.010 |
Why?
|
| Liposomes | 1 | 2006 | 132 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 19 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2005 | 69 | 0.010 |
Why?
|
| Back Pain | 1 | 2005 | 32 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2006 | 174 | 0.010 |
Why?
|
| Leukocytes | 1 | 2005 | 80 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 694 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2004 | 10 | 0.010 |
Why?
|
| Neutrophils | 1 | 2005 | 145 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2004 | 12 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 125 | 0.010 |
Why?
|
| Temperature | 1 | 2004 | 313 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2002 | 39 | 0.010 |
Why?
|
| Skin Absorption | 1 | 2002 | 16 | 0.010 |
Why?
|
| Diffusion | 1 | 2002 | 63 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2000 | 29 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2000 | 70 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2000 | 109 | 0.010 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2000 | 57 | 0.010 |
Why?
|
| Drug Stability | 1 | 1999 | 129 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 458 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 186 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1998 | 3 | 0.010 |
Why?
|
| Glucose | 1 | 1999 | 244 | 0.010 |
Why?
|